These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 25985242)

  • 1. Combined Immunosuppression Impairs Immunogenicity to Tetanus and Pertussis Vaccination Among Patients with Inflammatory Bowel Disease.
    Dezfoli S; Horton HA; Thepyasuwan N; Berel D; Targan SR; Vasiliauskas EA; Dubinsky M; Shih DQ; Kaur M; McGovern DP; Ippoliti A; Feldman EJ; Melmed GY
    Inflamm Bowel Dis; 2015 Aug; 21(8):1754-60. PubMed ID: 25985242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of a combined Tetanus, Diphtheria, recombinant acellular Pertussis vaccine (TdaP) in healthy Thai adults.
    Sirivichayakul C; Chanthavanich P; Limkittikul K; Siegrist CA; Wijagkanalan W; Chinwangso P; Petre J; Hong Thai P; Chauhan M; Viviani S
    Hum Vaccin Immunother; 2017 Jan; 13(1):136-143. PubMed ID: 27686283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lower Sustained Diphtheria and Pertussis Antibody Concentrations in Inflammatory Bowel Disease Patients.
    Caldera F; Saha S; Wald A; Garmoe CA; McCrone S; Megna B; Ley D; Reichelderfer M; Hayney MS
    Dig Dis Sci; 2018 Jun; 63(6):1532-1540. PubMed ID: 29594970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Humoral immunity 10 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine in the USA.
    Pool V; Tomovici A; Johnson DR; Greenberg DP; Decker MD
    Vaccine; 2018 Apr; 36(17):2282-2287. PubMed ID: 29573876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomised, double-blind, non-inferiority clinical trial on the safety and immunogenicity of a tetanus, diphtheria and monocomponent acellular pertussis (TdaP) vaccine in comparison to a tetanus and diphtheria (Td) vaccine when given as booster vaccinations to healthy adults.
    Thierry-Carstensen B; Jordan K; Uhlving HH; Dalby T; Sørensen C; Jensen AM; Heilmann C
    Vaccine; 2012 Aug; 30(37):5464-71. PubMed ID: 22776216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination of adults 65 years of age and older with tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Boostrix(®)): results of two randomized trials.
    Weston WM; Friedland LR; Wu X; Howe B
    Vaccine; 2012 Feb; 30(9):1721-8. PubMed ID: 22212127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hib antibody responses in infants following diphtheria, tetanus, acellular pertussis, and conjugated Haemophilus influenzae type b (Hib) combination vaccines with decreasing amounts of tetanus toxoid.
    Bernstein HH; Seyferth ER
    Vaccine; 2017 Dec; 35(48 Pt B):6707-6711. PubMed ID: 29054729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of maternal vaccination against diphtheria, tetanus, and pertussis on the avidity of infant antibody responses to a pertussis containing vaccine in Belgium.
    Caboré RN; Maertens K; Dobly A; Leuridan E; Van Damme P; Huygen K
    Virulence; 2017 Oct; 8(7):1245-1254. PubMed ID: 28277900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity, safety, and antibody persistence at 3, 5, and 10 years postvaccination in adolescents randomized to booster immunization with a combined tetanus, diphtheria, 5-component acellular pertussis, and inactivated poliomyelitis vaccine administered with a hepatitis B virus vaccine concurrently or 1 month apart.
    Embree J; Law B; Voloshen T; Tomovici A
    Clin Vaccine Immunol; 2015 Mar; 22(3):282-90. PubMed ID: 25540274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Broder KR; Cortese MM; Iskander JK; Kretsinger K; Slade BA; Brown KH; Mijalski CM; Tiwari T; Weston EJ; Cohn AC; Srivastava PU; Moran JS; Schwartz B; Murphy TV;
    MMWR Recomm Rep; 2006 Mar; 55(RR-3):1-34. PubMed ID: 16557217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK.
    Marlow R; Kuriyakose S; Mesaros N; Han HH; Tomlinson R; Faust SN; Snape MD; Pollard AJ; Finn A
    Vaccine; 2018 Apr; 36(17):2300-2306. PubMed ID: 29576304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults.
    Pichichero ME; Rennels MB; Edwards KM; Blatter MM; Marshall GS; Bologa M; Wang E; Mills E
    JAMA; 2005 Jun; 293(24):3003-11. PubMed ID: 15933223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age.
    Silfverdal SA; Assudani D; Kuriyakose S; Van Der Meeren O
    Hum Vaccin Immunother; 2014; 10(10):2795-8. PubMed ID: 25483640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel.
    Kretsinger K; Broder KR; Cortese MM; Joyce MP; Ortega-Sanchez I; Lee GM; Tiwari T; Cohn AC; Slade BA; Iskander JK; Mijalski CM; Brown KH; Murphy TV; ; ;
    MMWR Recomm Rep; 2006 Dec; 55(RR-17):1-37. PubMed ID: 17167397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of a tetanus toxoid, reduced diphtheria toxoid and three-component acellular pertussis vaccine in adults 19-64 years of age.
    Blatter M; Friedland LR; Weston WM; Li P; Howe B
    Vaccine; 2009 Jan; 27(5):765-72. PubMed ID: 19041352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Humoral immunity 10 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine.
    Tomovici A; Barreto L; Zickler P; Meekison W; Noya F; Voloshen T; Lavigne P
    Vaccine; 2012 Mar; 30(16):2647-53. PubMed ID: 22353673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and reactogenicity of a reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine as a single-dose booster in Singaporean adults.
    Chan SH; Tan PT; Han HH; Bock HL
    Singapore Med J; 2006 Apr; 47(4):286-90. PubMed ID: 16572239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine.
    America Academy of Pediatrics Commitee on Infectious Diseases
    Pediatrics; 2006 Mar; 117(3):965-78. PubMed ID: 16382131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined, reduced-antigen content tetanus, diphtheria, and acellular pertussis vaccine (Boostrix): a review of its use as a single-dose booster immunization in individuals aged 10-64 years in the US.
    Plosker GL
    BioDrugs; 2009; 23(4):253-67. PubMed ID: 19697967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tetanus, diphtheria, and acellular pertussis vaccination during pregnancy and reduced risk of infant acute respiratory infections.
    Khodr ZG; Bukowinski AT; Gumbs GR; Conlin AMS
    Vaccine; 2017 Oct; 35(42):5603-5610. PubMed ID: 28916245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.